IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model

Limited efficacy of immune checkpoint inhibitors in hepatocellular carcinoma (HCC) was observed in clinical trials, thus prompting investigation into combination therapy. Interleukin-6 (IL-6) has important roles in modeling immune responses in cancers. Here, we hypothesized that IL-6 blockade would...

Full description

Saved in:
Bibliographic Details
Published inBiochemical and biophysical research communications Vol. 486; no. 2; pp. 239 - 244
Main Authors Liu, Hu, Shen, Jun, Lu, Kai
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 29.04.2017
Subjects
Online AccessGet full text

Cover

Loading…